Erythropoietin (EPO) Biomarkers Market worth USD 1.06 billion by 2030
The report "Erythropoietin (EPO) Biomarkers Market by Type (Erythropoietin Alfa, Erythropoietin Zeta), Application (Anemic Disorders, Cancer, End-stage renal disorders), End User (Hospitals, Diagnostic Centers) – Global Forecast to 2030" is projected to reach USD 1.06 billion by 2030, from USD 0.69 billion in 2025, at a CAGR of 9.0% during the forecast period.
Browse 408 market data Tables and 57 Figures spread through 357 Pages and in-depth TOC on "Erythropoietin (EPO) Biomarkers Market by Type (Erythropoietin Alfa, Erythropoietin Zeta), Application (Anemic disorder, Cancer, End-stage renal disorder), End User (Hospitals, Diagnostic Centers) - Global Forecast to 2030"
View detailed Table of Content here - https://www.marketsandmarkets.com/Market-Reports/erythropoietin-epo-biomarkers-market-246612734.html
The Erythropoietin (EPO) biomarkers market is experiencing growth, driven by several key factors, including the increasing prevalence of CKD and anemia-related conditions and advancements in biomarker diagnostics and precision medicine.
The hospitals segment accounted for the largest share of the Erythropoietin (EPO) biomarkers market, by end user, in 2024.
Hospitals capture the dominant market share for EPO biomarkers among end users, relying on centralized immunoassay systems for high-volume anemia screening and therapy monitoring. These institutions expertly handle complex chronic kidney disease and oncology patients, integrating EPO assays with reticulocyte counts and ferritin levels for comprehensive diagnostics. Advanced laboratory infrastructure, skilled personnel, and established reimbursement pathways enable rapid testing turnaround, supporting precise dosing decisions for erythropoiesis-stimulating agents across inpatient and outpatient nephrology services.
During the forecast period, the cancer segment was the fastest-growing, by application.
Cancer was the fastest-growing application area in the EPO biomarkers market, driven by the growing number of chemotherapy-induced cases of anemia and the need for real-time monitoring of therapy. Oncology centers are increasingly using multiplex immunoassays to monitor EPO, reticulocytes, and ferritin levels to allow accurate dosing decisions for ESAs such as epoetin alfa. Biomarker-based clinical trials and precision medicine projects are accelerating adoption, especially in the case of biosimilars in hematological malignancies and solid cancers.
North America accounted for the largest regional share in the Erythropoietin (EPO) biomarkers market in 2024.
The market for Erythropoietin (EPO) biomarkers is segmented into North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. North America holds the largest share of the Erythropoietin (EPO) biomarkers market, reflecting its strong base of academic medical centers, integrated health systems, and diagnostics innovators that have rapidly adopted immunoassay-, multiplex-, and automated analyzer-based biomarker technologies. The region benefits from favorable reimbursement frameworks for anemia monitoring, early regulatory acceptance of advanced diagnostic platforms, and major government and payer initiatives supporting precision nephrology adoption. In addition, high levels of pharma and biotech investment in EPO-enabled clinical trials, real-world evidence generation, and decentralized study designs continue to reinforce North America's leading position in global EPO biomarker revenues.
Key players in the Erythropoietin (EPO) biomarkers market include Amgen Inc. (US), Biocon Ltd (India), Johnson & Johnson (US), F. Hoffmann-La Roche Ltd (Switzerland), Merck KGaA (Germany), Pfizer Inc. (US), Siemens Healthineers (Germany), and 3SBio Group (China).
About MarketsandMarkets™
MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report.
MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe.
Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem.
The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.
Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts.
To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter , LinkedIn and Facebook .
Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
Visit Our Website: https://www.marketsandmarkets.com
- Triangulate with your Own Data
- Get Data as per your Format and Definition
- Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
- Any level of Personalization
- What are the Known and Unknown Adjacencies Impacting the Erythropoietin (EPO) Biomarkers Market
- What will your New Revenue Sources be?
- Who will be your Top Customer; what will make them switch?
- Defend your Market Share or Win Competitors
- Get a Scorecard for Target Partners
